Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | 0.00% | +25.00% | 0.00% |
05-08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
03-05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
End-of-day quotes
Sector Other Biotechnology & Medical Research
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
21.47M | - | - | - | - | - | |
56.65B | - | |||||
39.44B | ||||||
39.03B | ||||||
26.86B | ||||||
26.75B |
- Stock Market
- Equities
- IVX Stock
- Charts Invion Limited
- Sector Chart